Conference
A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma.
Authors
Sridhar SS; Canil CM; Mukherjee SD; Winquist E; Elser C; Eisen A; Chung A; Ko Y
Volume
28
Pagination
pp. tps231-tps231
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2010
DOI
10.1200/jco.2010.28.15_suppl.tps231
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X